Rare diseases impose a disproportionate burden on patients and the health system. Critically evaluate India's policy response.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →Rare diseases are mostly genetic. They are hard to diagnose and costly to treat, and few medicines exist for them [1]. A small number of patients therefore carry a very heavy burden. India's response is built on the National Policy for Rare Diseases (NPRD), 2021 [2]. It is real progress, but it does more to pay for treatment than to make treatment easier to reach.
Strengths of the policy response
- Dedicated framework: MoHFW approved NPRD in March 2021. It aims to cut high treatment costs and to promote indigenous research through a National Consortium [2].
- Financial protection: patients get support of up to Rs 50 lakh each for treatment at notified Centres of Excellence (CoEs) [3].
- Indigenous therapy: India ran its first human gene therapy trial for haemophilia A at CMC Vellore [4]. The results were published in the New England Journal of Medicine [1].
- Genomic base: GenomeIndia has sequenced 10,000 genomes across 84 populations, which helps diagnosis suited to Indian patients. ICMR is also widening coverage of rare genetic diseases [1].
Weaknesses and gaps
- Capped grant, lifelong need: many rare diseases need medicine for life, so a fixed cap runs out while the illness continues. The grant pays part of the cost but does not lower it [3].
- Access depends on location: support covers treatment only at CoEs [3]. Travel and long stays near the hospital are not covered, so poor and remote families lose out first.
- Late diagnosis: diagnosis remains difficult [1]. When detection is late, money reaches patients after avoidable damage has occurred.
- Research-to-patient gap: gene therapy is still at the trial stage and reaches few people [4]. The Consortium has not yet turned research into low-cost products.
- Data governance: large genomic databases raise questions of consent, privacy and benefit-sharing under the Digital Personal Data Protection Act, 2023.
Verdict and way forward
Overall, India has moved from ad hoc relief to a structured, research-backed policy. However, the response still pays part of the cost rather than lowering it. The National Consortium should take indigenous one-time therapies like the CMC Vellore model from trial to CoEs. This could let the Rs 50 lakh cap pay for a cure instead of a few years of medicine. Diagnosis should be expanded beyond CoEs, and GenomeIndia data should be used for early detection. Together, these steps would bring rare-disease care in line with Article 21's right to health and SDG 3.8 (universal health coverage).
Sources
- 1PIB press release: Dr Jitendra Singh at THE WEEK Health Summit 2026rare disease burden (diagnosis, cost, few medicines); NEJM publication; GenomeIndia 10,000 genomes and 84 populations; ICMR rare disease coverage
- 2MoHFW (PIB): National Policy for Rare Diseases, 2021approval in March 2021; aim to reduce treatment cost; National Consortium for indigenous research
- 3MoHFW (PIB): Financial support under NPRD 2021up to Rs 50 lakh per patient for treatment at notified Centres of Excellence
- 4DST: National Science Day 2024 address (haemophilia A gene therapy trial)India's first human gene therapy trial for haemophilia A at CMC Vellore